2020. BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician’s Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI. SKIN The Journal of Cutaneous Medicine. 4, 5 (Sep. 2020), s29. DOI:https://doi.org/10.25251/skin.4.supp.29.